@misc{oai:repo.qst.go.jp:00079772,
 author = {Shimada, Hitoshi and Matsuoka, Kiwamu and Kubota, Manabu and Takahata, Keisuke and Takado, Yuhei and Seki, Chie and Ono, Maiko and Sahara, Naruhiko and Kawamura, Kazunori and Ming-Rong, Zhang and Higuchi, Makoto and Shimada, Hitoshi and Matsuoka, Kiwamu and Kubota, Manabu and Takahata, Keisuke and Takado, Yuhei and Seki, Chie and Ono, Maiko and Sahara, Naruhiko and Kawamura, Kazunori and Ming-Rong, Zhang and Higuchi, Makoto},
 month = {Feb},
 note = {Background and Aims: Our previous studies demonstrated that 18F-PM-PBB3 (18F-APN-1607) uptake may reflect characteristic distributions of tau pathologies in 4-repeat tauopathies including progressive supranuclear palsy (PSP). The present study aimed to investigate the association among 18F-PM-PBB3 uptake, neurodegenerative biomarker level, and clinical symptoms in PSP with Richardson syndrome (PSP-RS) patients.
Methods: 21 patients with probable PSP-RS underwent PET scans with 18F-PM-PBB3 and 11C-PiB for estimating regional tau and Aβ deposition. Plasma neurofilament light chain (NfL) levels were also checked as a neurodegenerative biomarker. Parametric 18F-PM-PBB3- and 11C-PiB- images were generated by voxel-based calculation of the standardized uptake value ratio (SUVR) to the cerebellar cortex. Three patients, who were diagnosed as amyloid-positive by visual assessment of 11C-PiB SUVR image, and two patients lacking some data (PET or NfL) were excluded. Finally, the other 18PiB-negative PSP-RS patients were included for further analyses. Regional 18F-PM-PBB3 SUVR was estimated in dentate, midbrain, subthalamus, striatum, pre- and post-central gyri in addition to PSP tau PET meta-ROI. We assessed Pearson’s correlation of regional 18F-PM-PBB3 SUVR with plasma NfL levels and motor severity assessed by PSP rating scale.
Results: Plasma NfL levels showed positive correlation with 18F-PM-PBB3 SUVR in striatum, pre- and post-central gyri as well as PSP tau PET meta-ROI (r = 0.77, 0.98, 0.95, and 0.78; p < 0.05, followed by Bonferroni correction), and a trend toward significance in midbrain and dentate (r = 0.68 and 0.51; p = 0.008 and 0.043, without multiple comparison). PSP rating scale score positively correlated with plasma NFL (r = 0.73; p < 0.01, followed by Bonferroni correction), and there were trends towards significance between PSP rating scale and 18F-PM-PBB3 SUVR in midbrain and PSP tau PET meta-ROI (r = 0.66 and 0.65; p = 0.01 and 0.03, without multiple comparison).
Conclusions: Accumulations of PM-PBB3 may reflect neurotoxic tau pathologies in PSP-RS, in tight association with clinical symptoms., Takeda Expert Conference on Parkinson's Disease 2020},
 title = {18F-PM-PBB3 (18F-APN-1607) uptake associates with plasma NfL level and motor disability in patients with progressive supranuclear palsy},
 year = {2020}
}